Department of Internal Medicine and Biomedical Sciences, University of Parma, Italy.
Metabolism. 2012 Dec;61(12):1666-73. doi: 10.1016/j.metabol.2012.04.004. Epub 2012 May 1.
Diabetic nephropathy (DN) is the major cause of end-stage renal disease in Western countries and its prevalence continues to increase (United States Renal Data System 2010, http://www.usrds.org/). Treatments currently utilised for DN provide only partial renoprotection, hence the need to identify new targets for therapeutic intervention. Metabolic and haemodynamic abnormalities have been implicated in the pathogenesis of DN, triggering the activation of intracellular signaling molecules that lead to the dysregulation of vascular growth factors and cytokines, such as vascular endothelial growth factor (VEGF) and angiopoietins, important players in the functional and structural regulation of the glomerular filtration barrier. This review focuses on the importance of VEGF-A and angiopoietins in kidney physiology and in the diabetic kidney, exploring their potential therapeutic role in the prevention and delay of diabetic glomerulopathy.
糖尿病肾病（DN）是西方国家终末期肾病的主要原因，其患病率持续上升（美国肾脏数据系统 2010 年，http://www.usrds.org/）。目前用于治疗 DN 的方法仅提供部分肾脏保护，因此需要确定新的治疗靶点。代谢和血液动力学异常与 DN 的发病机制有关，触发细胞内信号分子的激活，导致血管生长因子和细胞因子（如血管内皮生长因子[VEGF]和血管生成素）的失调，这些因子在肾小球滤过屏障的功能和结构调节中起着重要作用。本文重点介绍了 VEGF-A 和血管生成素在肾脏生理学和糖尿病肾脏中的重要性，探讨了它们在预防和延缓糖尿病肾小球病变中的潜在治疗作用。
